The Use of Novel Implantable Cancer Vaccines for the Treatment of Oral Cancer

使用新型植入式癌症疫苗治疗口腔癌

基本信息

批准号：
8565916
负责人：
Simon Young
金额：
$ 10.66万
依托单位：
HARVARD MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-08-26 至 2015-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8565916
关键词：
Accounting Address Affect CD8B1 gene Cancer Patient Cancer Vaccines Carcinoma in Situ Cessation of life Combined Modality Therapy Combined Vaccines Comorbidity Cytosine Cytotoxic T-Lymphocyte-Associated Protein 4 Cytotoxic T-Lymphocytes Deglutition Dendritic Cells Development Dose Effectiveness Epidermal Growth Factor Receptor Face Freezing Glioma Goals Granulocyte-Macrophage Colony-Stimulating Factor Guanosine Hypochlorous Acid Immune response Immunotherapeutic agent Impairment In Situ In Vitro Laboratories Malignant Neoplasms Malignant Squamous Cell Neoplasm Methods Modality Modeling Monoclonal Antibodies Morbidity - disease rate Oligonucleotides Operative Surgical Procedures Oral Play Polymers Pre-Clinical Model Preparation Quality of life Radiation therapy Reconstructive Surgical Procedures Recruitment Activity Role Study Section Survival Rate Techniques Technology Testing Therapeutic Therapeutic Effect Toxic effect Transplantation Tumor Immunity Ultraviolet B Radiation Ultraviolet Rays Woman Work base cancer immunotherapy chemotherapy design design and construction human monoclonal antibodies immunogenic immunogenicity improved in vivo innovation killings lymph nodes malignant mouth neoplasm melanoma men mouth squamous cell carcinoma novel novel strategies oral immunotherapy oxidation programs public health relevance response spatiotemporal tool tumor vaccine efficacy

项目摘要

DESCRIPTION (provided by applicant): Oral squamous cell cancer (OSCC) is the sixth most common cancer worldwide and accounts for 2% of all malignancies in the USA. In this year alone, 40,000 men and women will develop OSCC, and unfortunately, only two-thirds of these OSCC patients will survive more than five years. While the past decades have seen advances in ablative/reconstructive surgery, radiation therapy, and chemotherapy, the overall survival rate of OSCC patients has not improved significantly, and there are multiple co-morbidities which arise from treatment which may negatively affect quality of life. Thus, there is a real need for innovative new approaches to treating oral squamous cell cancer. Cancer immunotherapy has arisen as a novel treatment modality for several cancers, and an implantable, polymeric cancer vaccine has been developed by the Mooney laboratory which shows impressive tumor killing in both melanoma and glioma preclinical models. Our goal is to evaluate this promising cancer vaccine technology for use in oral squamous cell carcinoma. Our overall hypothesis is that an in situ cancer vaccine construct able to provide appropriate spatiotemporal presentation of bioactive factors to host dendritic cells can induce anti-tumor immunity. The studies outlined in this proposal seek to determine the effectiveness of the implantable cancer vaccine for treating OSCC, to optimize the various components of the cancer vaccine for maximum potency, and to explore any synergistic effects which arise by combining this vaccine with other immunotherapeutic tools such as tumor-specific monoclonal antibodies. Overall, these studies are anticipated to enhance our understanding of the role dendritic cells and tumor-specific cytotoxic T cells play in the treatment of OSCC, and may also contribute to the development of novel immunotherapies for OSCC.

描述（由申请人提供）：口腔鳞状细胞癌 (OSCC) 是全球第六大常见癌症，占美国所有恶性肿瘤的 2%。仅今年一年，就有 40,000 名男性和女性患上 OSCC，不幸的是，这些 OSCC 患者中只有三分之二能够存活五年以上。尽管过去几十年来消融/重建手术、放射治疗和化疗取得了进展，但 OSCC 患者的总体生存率并未显着提高，并且治疗中出现多种并发症，可能会对生活质量产生负面影响。因此，确实需要创新的新方法来治疗口腔鳞状细胞癌。癌症免疫疗法已成为多种癌症的一种新型治疗方式，穆尼实验室已开发出一种可植入的聚合癌症疫苗，该疫苗在黑色素瘤和神经胶质瘤临床前模型中显示出令人印象深刻的肿瘤杀灭作用。我们的目标是评估这种有前途的癌症疫苗技术在口腔鳞状细胞癌中的应用。我们的总体假设是，能够向宿主树突细胞提供生物活性因子的适当时空呈现的原位癌症疫苗构建体可以诱导抗肿瘤免疫。该提案中概述的研究旨在确定植入式癌症疫苗治疗 OSCC 的有效性，优化癌症疫苗的各种成分以获得最大效力，并探索将该疫苗与其他免疫治疗工具（例如作为肿瘤特异性单克隆抗体。总体而言，这些研究预计将增强我们对树突状细胞和肿瘤特异性细胞毒性 T 细胞在 OSCC 治疗中的作用的理解，并且也可能有助于开发针对 OSCC 的新型免疫疗法。